What is the current valuation of the Hereditary Angioedema Therapeutics Market?

The market valuation was 6.71 USD Billion in 2024. Read More

What is the projected market size for the Hereditary Angioedema Therapeutics Market by 2035?

The market is projected to reach 40.37 USD Billion by 2035. Read More

What is the expected CAGR for the Hereditary Angioedema Therapeutics Market during the forecast period 2025 - 2035?

The expected CAGR is 17.72% during the forecast period 2025 - 2035. Read More

Which companies are considered key players in the Hereditary Angioedema Therapeutics Market?

Key players include Takeda Pharmaceutical Company Limited, CSL Behring, Shire, BioCryst Pharmaceuticals, Inc., Sobi, Pharming Group N.V., KalVista Pharmaceuticals, Inc., and Acrotech Biopharma LLC. Read More

How does the market segment by treatment type for Hereditary Angioedema?

The market segments into Prophylaxis and On-demand treatments, with valuations of 3.36 and 3.35 USD Billion respectively in 2024. Read More

What routes of administration are prevalent in the Hereditary Angioedema Therapeutics Market?

The prevalent routes of administration include Intravenous, Subcutaneous, and Oral, with respective valuations of 1.34, 2.01, and 3.36 USD Billion in 2024. Read More

What distribution channels are utilized in the Hereditary Angioedema Therapeutics Market?

Distribution channels include Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy, with valuations of 2.68, 2.01, and 1.02 USD Billion respectively in 2024. Read More

What are the projected market trends for Type I and Type II Hereditary Angioedema?

Type I and Type II are projected to have valuations of 3.36 and 3.35 USD Billion respectively in 2024, indicating a balanced market. Read More

How is the competitive landscape evolving in the Hereditary Angioedema Therapeutics Market?

The competitive landscape is evolving with key players like Takeda and CSL Behring leading the market, suggesting a dynamic environment for innovation. Read More

Hereditary Angioedema Therapeutics Market

Q: What are the main drug classes in the Hereditary Angioedema Therapeutics Market?

The main drug classes include C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others. Read More

ID: MRFR/HC/10642-HCR

128 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Hereditary Angioedema Therapeutics Market Research Report Information by Type (Type I, Type II), By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others), By Treatment (Prophylaxis - Long-term Prophylaxis, Short-term Prophylaxis, On-demand), By Route of Administration (Intravenous, Subcutaneous, Oral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and By Region (North America, Europe, Asia Pacific, Rest of the World) - Market Forecast Till 2035

Hereditary Angioedema Therapeutics Market Infographic

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Type (USD Billion) | |
  1. 4.1.1 Type I | |
  2. 4.1.2 Type II |
2. 4.2 Healthcare, BY Drug Class (USD Billion) | |
  1. 4.2.1 C1 Esterase Inhibitor | |
  2. 4.2.2 Selective Bradykinin B2 Receptor Antagonist | |
  3. 4.2.3 Kallikrein Inhibitor | |
  4. 4.2.4 Others |
3. 4.3 Healthcare, BY Treatment (USD Billion) | |
  1. 4.3.1 Prophylaxis | |
  2. 4.3.2 On-demand |
4. 4.4 Healthcare, BY Route of Administration (USD Billion) | |
  1. 4.4.1 Intravenous | |
  2. 4.4.2 Subcutaneous | |
  3. 4.4.3 Oral |
5. 4.5 Healthcare, BY Distribution Channel (USD Billion) | |
  1. 4.5.1 Hospital Pharmacy | |
  2. 4.5.2 Retail Pharmacy | |
  3. 4.5.3 Online Pharmacy |
6. 4.6 Healthcare, BY Region (USD Billion) | |
  1. 4.6.1 North America | | |
    1. 4.6.1.1 US | | |
    2. 4.6.1.2 Canada | |
  2. 4.6.2 Europe | | |
    1. 4.6.2.1 Germany | | |
    2. 4.6.2.2 UK | | |
    3. 4.6.2.3 France | | |
    4. 4.6.2.4 Russia | | |
    5. 4.6.2.5 Italy | | |
    6. 4.6.2.6 Spain | | |
    7. 4.6.2.7 Rest of Europe | |
  3. 4.6.3 APAC | | |
    1. 4.6.3.1 China | | |
    2. 4.6.3.2 India | | |
    3. 4.6.3.3 Japan | | |
    4. 4.6.3.4 South Korea | | |
    5. 4.6.3.5 Malaysia | | |
    6. 4.6.3.6 Thailand | | |
    7. 4.6.3.7 Indonesia | | |
    8. 4.6.3.8 Rest of APAC | |
  4. 4.6.4 South America | | |
    1. 4.6.4.1 Brazil | | |
    2. 4.6.4.2 Mexico | | |
    3. 4.6.4.3 Argentina | | |
    4. 4.6.4.4 Rest of South America | |
  5. 4.6.5 MEA | | |
    1. 4.6.5.1 GCC Countries | | |
    2. 4.6.5.2 South Africa | | |
    3. 4.6.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Takeda Pharmaceutical Company Limited (JP) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 CSL Behring (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Shire (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 BioCryst Pharmaceuticals, Inc. (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Sobi (SE) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Pharming Group N.V. (NL) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 KalVista Pharmaceuticals, Inc. (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Acrotech Biopharma LLC (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TYPE |
7. 6.4 US MARKET ANALYSIS BY DRUG CLASS |
8. 6.5 US MARKET ANALYSIS BY TREATMENT |
9. 6.6 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
10. 6.7 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
11. 6.8 CANADA MARKET ANALYSIS BY TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY DRUG CLASS |
13. 6.10 CANADA MARKET ANALYSIS BY TREATMENT |
14. 6.11 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
15. 6.12 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
16. 6.13 EUROPE MARKET ANALYSIS |
17. 6.14 GERMANY MARKET ANALYSIS BY TYPE |
18. 6.15 GERMANY MARKET ANALYSIS BY DRUG CLASS |
19. 6.16 GERMANY MARKET ANALYSIS BY TREATMENT |
20. 6.17 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
21. 6.18 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
22. 6.19 UK MARKET ANALYSIS BY TYPE |
23. 6.20 UK MARKET ANALYSIS BY DRUG CLASS |
24. 6.21 UK MARKET ANALYSIS BY TREATMENT |
25. 6.22 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
26. 6.23 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
27. 6.24 FRANCE MARKET ANALYSIS BY TYPE |
28. 6.25 FRANCE MARKET ANALYSIS BY DRUG CLASS |
29. 6.26 FRANCE MARKET ANALYSIS BY TREATMENT |
30. 6.27 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
31. 6.28 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
32. 6.29 RUSSIA MARKET ANALYSIS BY TYPE |
33. 6.30 RUSSIA MARKET ANALYSIS BY DRUG CLASS |
34. 6.31 RUSSIA MARKET ANALYSIS BY TREATMENT |
35. 6.32 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
36. 6.33 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
37. 6.34 ITALY MARKET ANALYSIS BY TYPE |
38. 6.35 ITALY MARKET ANALYSIS BY DRUG CLASS |
39. 6.36 ITALY MARKET ANALYSIS BY TREATMENT |
40. 6.37 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
41. 6.38 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
42. 6.39 SPAIN MARKET ANALYSIS BY TYPE |
43. 6.40 SPAIN MARKET ANALYSIS BY DRUG CLASS |
44. 6.41 SPAIN MARKET ANALYSIS BY TREATMENT |
45. 6.42 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
46. 6.43 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
47. 6.44 REST OF EUROPE MARKET ANALYSIS BY TYPE |
48. 6.45 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS |
49. 6.46 REST OF EUROPE MARKET ANALYSIS BY TREATMENT |
50. 6.47 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
51. 6.48 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
52. 6.49 APAC MARKET ANALYSIS |
53. 6.50 CHINA MARKET ANALYSIS BY TYPE |
54. 6.51 CHINA MARKET ANALYSIS BY DRUG CLASS |
55. 6.52 CHINA MARKET ANALYSIS BY TREATMENT |
56. 6.53 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
57. 6.54 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
58. 6.55 INDIA MARKET ANALYSIS BY TYPE |
59. 6.56 INDIA MARKET ANALYSIS BY DRUG CLASS |
60. 6.57 INDIA MARKET ANALYSIS BY TREATMENT |
61. 6.58 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
62. 6.59 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
63. 6.60 JAPAN MARKET ANALYSIS BY TYPE |
64. 6.61 JAPAN MARKET ANALYSIS BY DRUG CLASS |
65. 6.62 JAPAN MARKET ANALYSIS BY TREATMENT |
66. 6.63 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
67. 6.64 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
68. 6.65 SOUTH KOREA MARKET ANALYSIS BY TYPE |
69. 6.66 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS |
70. 6.67 SOUTH KOREA MARKET ANALYSIS BY TREATMENT |
71. 6.68 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
72. 6.69 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
73. 6.70 MALAYSIA MARKET ANALYSIS BY TYPE |
74. 6.71 MALAYSIA MARKET ANALYSIS BY DRUG CLASS |
75. 6.72 MALAYSIA MARKET ANALYSIS BY TREATMENT |
76. 6.73 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
77. 6.74 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
78. 6.75 THAILAND MARKET ANALYSIS BY TYPE |
79. 6.76 THAILAND MARKET ANALYSIS BY DRUG CLASS |
80. 6.77 THAILAND MARKET ANALYSIS BY TREATMENT |
81. 6.78 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
82. 6.79 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
83. 6.80 INDONESIA MARKET ANALYSIS BY TYPE |
84. 6.81 INDONESIA MARKET ANALYSIS BY DRUG CLASS |
85. 6.82 INDONESIA MARKET ANALYSIS BY TREATMENT |
86. 6.83 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
87. 6.84 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
88. 6.85 REST OF APAC MARKET ANALYSIS BY TYPE |
89. 6.86 REST OF APAC MARKET ANALYSIS BY DRUG CLASS |
90. 6.87 REST OF APAC MARKET ANALYSIS BY TREATMENT |
91. 6.88 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
92. 6.89 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
93. 6.90 SOUTH AMERICA MARKET ANALYSIS |
94. 6.91 BRAZIL MARKET ANALYSIS BY TYPE |
95. 6.92 BRAZIL MARKET ANALYSIS BY DRUG CLASS |
96. 6.93 BRAZIL MARKET ANALYSIS BY TREATMENT |
97. 6.94 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
98. 6.95 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
99. 6.96 MEXICO MARKET ANALYSIS BY TYPE |
100. 6.97 MEXICO MARKET ANALYSIS BY DRUG CLASS |
101. 6.98 MEXICO MARKET ANALYSIS BY TREATMENT |
102. 6.99 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
103. 6.100 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
104. 6.101 ARGENTINA MARKET ANALYSIS BY TYPE |
105. 6.102 ARGENTINA MARKET ANALYSIS BY DRUG CLASS |
106. 6.103 ARGENTINA MARKET ANALYSIS BY TREATMENT |
107. 6.104 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
108. 6.105 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
109. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
110. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS |
111. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT |
112. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
113. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
114. 6.111 MEA MARKET ANALYSIS |
115. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
116. 6.113 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS |
117. 6.114 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT |
118. 6.115 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
119. 6.116 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
120. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
121. 6.118 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS |
122. 6.119 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT |
123. 6.120 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
124. 6.121 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
125. 6.122 REST OF MEA MARKET ANALYSIS BY TYPE |
126. 6.123 REST OF MEA MARKET ANALYSIS BY DRUG CLASS |
127. 6.124 REST OF MEA MARKET ANALYSIS BY TREATMENT |
128. 6.125 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
129. 6.126 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
130. 6.127 KEY BUYING CRITERIA OF HEALTHCARE |
131. 6.128 RESEARCH PROCESS OF MRFR |
132. 6.129 DRO ANALYSIS OF HEALTHCARE |
133. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
134. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
135. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE |
136. 6.133 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
137. 6.134 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
138. 6.135 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE) |
139. 6.136 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion) |
140. 6.137 HEALTHCARE, BY TREATMENT, 2024 (% SHARE) |
141. 6.138 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion) |
142. 6.139 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
143. 6.140 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
144. 6.141 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE) |
145. 6.142 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion) |
146. 6.143 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
147. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
148. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.2.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
149. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.3.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
150. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.4.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
151. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.5.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
152. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.6.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
153. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.7.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
154. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.8.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
155. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.9.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
156. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.10.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
157. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.11.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
158. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.12.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
159. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.13.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
160. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.14.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
161. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.15.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
162. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.16.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
163. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.17.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
164. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.18.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
165. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.19.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
166. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.20.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
167. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.21.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
168. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.22.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
169. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.23.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
170. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.24.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
171. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.25.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
172. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.26.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
173. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.27.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
174. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.28.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
175. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.29.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
176. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY TREATMENT, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  5. 7.30.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
177. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
178. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

Type I
Type II

Healthcare By Drug Class (USD Billion, 2025-2035)

C1 Esterase Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Kallikrein Inhibitor
Others

Healthcare By Treatment (USD Billion, 2025-2035)

Prophylaxis
On-demand

Healthcare By Route of Administration (USD Billion, 2025-2035)

Intravenous
Subcutaneous
Oral

Healthcare By Distribution Channel (USD Billion, 2025-2035)

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓